JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Sutro Biopharma (NASDAQ:STRO), maintaining a price target of $17.
April 03, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Sutro Biopharma, maintaining a price target of $17.
The reiteration of a Market Outperform rating and the maintenance of a $17 price target by a reputable analyst like Reni Benjamin from JMP Securities could positively influence investor sentiment towards STRO. This endorsement reaffirms the analyst's confidence in the company's potential, likely encouraging both current and potential investors about STRO's future prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100